|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Study** | **N0 of patients** | **Prophylactic GEA** | **Technical success** | **Clinical success** | **Adverse events** | **Reintervention** | **Survival (days)** |
| **Overall** | **Biliary** | **Duodenal** | **Overall** | **Biliary** | **Duodenal** | N0 of pts | Time of AE (days) | N0 of pts | RBO | Time to RBO (days) | RDO | Time to RDO (days) | N0 of pts | Mean | Median | SD | 95% CI | IQR | Range |
| SURGICAL DOUBLE BYPASS | Levi, 1982 | 18 | NA | NA | 18 | NA | NA | 0 | NA | NA | NA | NA | NA | 180 | - | - | - | - | 90-420 |
| Wongsuwanporn, 1983 | 26 | NA | NA | NA | NA | NA | 9 | 167 | NA | NA | NA | NA | - | 297 | - | - | - | - |
| Lee, 1984 | 65 | NA | NA | 58 | NA | NA | 7 | NA | NA | NA | NA | NA |
| Parker, 1985 | 13 | NA | NA | 9 | NA | NA | 4 | NA | NA | NA | NA | NA | 147 | - | 114 | - | - | 60-360 |
| Ferla, 1987 | 14 | 14 | - | 1 | - | - | NA | - | 2 | NA | NA | NA | NA | 14 | 19 | - | - | - | - | - |
| Singh, 1990 | 70 | 20 | NA | 68 | NA | NA | 59 | NA | NA | NA | 3 | NA | NA | NA | CDJ + GEA: 183 | - | - | - | - | - |
| CCJ + GEA: 288 |
| Casaccia, 1999 | 2 | 0 | 2 | 2 | 2 | 2 | 2 | 2 | 0 | NA | NA | NA | NA | NA |
| Hamade, 2005 | 8 | 5 | NA | NA | 1 | 1 | NA | NA | NA | 8 | - | 120 | - | - | - | 39-420 |
| Hao, 2005 | 22 | 22 | - | 22 | - | - | 17 | - | 0 | NA | 0 | NA | NA | NA | - | 240 | - | - | - | 45-240 |
| Khan, 2005 | 2 | 0 | NA | NA | 1 | 158 | 1 | 1 | 158 | NA | NA |
| Mortenson, 2005 | 38 | NA | NA | NA | 9 | NA | NA | NA | NA | NA | 210 | - | - | - | - | - |
| Tang, 2005 | 35 | NA | NA | 35 | NA | NA | 28 | NA | 17 | NA | NA | NA | NA | NA | - | 30 | - | - | - | - |
| Ghanem, 2006 | 8 | 3 | NA | NA | 2 | NA | NA | NA | NA | NA |
| Lesurtel, 2006 | 83 | 72 | NA | NA | 22 | NA | 7 | 3 | 340 | 4 | 240 | NA | - | 276 | - | - | - | 30-1320 |
| Mann, 2009 | 102 | 92 | - | 102 | - | - | NA | - | 27 | NA | 1 | NA | NA | NA | - | 285 | - | - | - | - |
|  | **Study** | **N0 of patients** | **Prophylactic GEA** | **Technical success** | **Clinical success** | **Adverse events** | **Reintervention** | **Survival (days)** |
| **Overall** | **Biliary** | **Duodenal** | **Overall** | **Biliary** | **Duodenal** | N0 of pts | Time of AE (days) | N0 of pts | RBO | Time to RBO (days) | RDO | Time to RDO (days) | N0 of pts | Mean | Median | SD | 95% CI | IQR | Range |
| SURGICAL DOUBLE BYPASS | Ausania, 2012 | 50 | 50 | NA | NA | 25 | NA | 3 | NA | NA | NA | - | 438 | - | - | - | - |
| Lyons, 2012 | 60 | 50 | NA | NA | 24 | NA | 24 | NA | NA | NA |
| Malde, 2012 | 48 | NA | NA | 48 | NA | NA | 11 | NA | NA | NA | NA | NA | - | 105 | - | - | - | - |
| Valeshabad, 2013 | 3 | 0 | NA | NA | NA | NA | NA | NA | NA | NA |
| Bartlett, 2014 | 351 | NA | NA | NA | 58 | NA | 49 | NA | NA | NA |
| Kohan, 2014 | 42 | 28 | NA | NA | 18 | NA | 3 | NA | NA | NA | 330 | - | - | - | - | 90-510 |
| Kofokotsios, 2015 | 11 | 11 | - | 11 | - | - | 7 | - | 2 | NA | NA | NA | NA | 11 | 306 (95% CI: 150-463) | 157 (95% CI: 0-411) | - | - | - | - |
| Williamson, 2015 | 59 | 59 | - | NA | - | - | NA | - | 48 | NA | 20 | NA | NA | NA |
| Fu, 2016 | 31 | 31 | - | NA | - | - | 29 | - | 11 | NA | NA | NA | NA | 31 | 428 | - | 223 | - | - | - |
| Giuliani, 2016 | 12 | 0 | NA | NA | 0 | NA | NA | NA | NA | 12 | - | 378 | - | 3.77-21.43 |  - | - |

Table, SDC3. Outcomes of studies dealing with surgical double bypass

GEA – gastroenteric anastomosis; AE – adverse event; RBO – recurrent biliary obstruction; RDO – recurrent duodenal obstruction; SD – standard deviation; CI – confidence interval; IQR – interquartile range; NA – not available; CDJ – choledochojejunostomy; CCJ – cholecystojejunostomy